Brean Likes Nektar Therapeutics' Upcoming Launches; Assumes Coverage At Buy
September 30, 2016 at 08:34 AM EDT
Brean Capital assumes coverage of Nektar Therapeutics (NASDAQ: NKTR) with Buy rating and $23 price target on strong growth in royalties ...
